Bone marrow immunohistology of plasma cell neoplasms

Wei, Andrew H.; Juneja, Surender

doi:10.1136/jcp.56.6.406

Cited by 45 publications

(46 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[14][15][16][17] The limited use of flow cytometry in the analysis of myeloma has probably been due to the well-documented discrepancy in the plasma cell percentage observed between flow cytometry and conventional microscopy in overall enumeration of plasma cells in bone marrow samples from myeloma patients.…”

Section: Plasma Cell Enumerationmentioning

confidence: 99%

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Rawstron¹,

Órfão²,

Beksaç³

et al. 2008

Haematologica

440

514

View full text Add to dashboard Cite

The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice in participating laboratories. The second aimed to resolve outstanding technical issues and develop a consensus approach to analysis of plasma cells. The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease. A range of technical recommendations were identified, including: 1) CD38, CD138 and CD45 should all be included in at least one tube for plasma cell identification and enumeration. The primary gate should be based on CD38 vs. CD138 expression; 2) after treatment, clonality assessment is only likely to be informative when combined with immunophenotype to detect abnormal cells. Flow cytometry is suitable for demonstrating a stringent complete remission; 3) for detection of abnormal plasma cells, a minimal panel should include CD19 and CD56. A preferred panel would also include CD20, CD117, CD28 and CD27; 4) discrepancies between the percentage of plasma cells detected by flow cytometry and morphology are primarily related to sample quality and it is, therefore, important to determine that marrow elements are present in follow-up samples, particularly normal plasma cells in MRD negative cases.

show abstract

Section: Plasma Cell Enumerationmentioning

confidence: 99%

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Rawstron¹,

Órfão²,

Beksaç³

et al. 2008

Haematologica

440

514

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12][13][14] Syndecan-1 (CD138) is expressed by malignant plasma cells from the majority of MM cell lines and patient specimens. [15][16][17] Furthermore, during normal B-cell development, CD138 expression is highly specific for terminally differentiated normal plasma cells because it is absent on highly proliferative normal plasmablasts and all earlier B-cell stages. [17][18][19][20] Therefore, we hypothesized that if clonogenic B cells represent putative MM stem cells, they should lack CD138 expression.…”

Section: Introductionmentioning

confidence: 99%

Characterization of clonogenic multiple myeloma cells

Matsui

Huff

Wang

et al. 2004

Blood

721

684

View full text Add to dashboard Cite

“…In such reactive cases, Plasma Cells (PCs) usually account for 10%-20% of cells in bone marrow trephine biopsy sections and rarely exceed 50% [3][4][5]. Herein we report an unusual case of bone marrow aplasia associated with prominent atypical plasma cell proliferation (96% of all nucleated cells exhibited transient pancytopenia) and hypoplastic bone marrow.…”

Section: Introductionmentioning

confidence: 99%

“…Serology was negative for Epstein-Barr virus (EBV), Cytomegalovirus (CMV), parvovirus, and Human Immunodeficiency Virus (HIV). Serum globulin was 3 g/dl [1][2][3][4][5] and albumin was 2.7 g/dl. Serum level of IgG, IgA, and IgM was 844, 171, and 49 mg/dl, respectively.…”

Section: Case Reportmentioning

confidence: 99%

“…Reactive bone marrow plasmacytosis occurs in association with a variety of conditions, such as chronic infections, autoimmune diseases, connective tissue and chronic granulomatous disorders, diabetes mellitus, hypersensitivity states, drug-related agranulocytosis, iron deficiency, megaloblastic and hemolytic anemia, hemopoietic and non-hemopoietic malignant diseases, angio-immunoblastic lymphadenopathy, and multicentric Castleman's disease [1][2][3]. In such reactive cases, Plasma Cells (PCs) usually account for 10%-20% of cells in bone marrow trephine biopsy sections and rarely exceed 50% [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation